<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02866448</url>
  </required_header>
  <id_info>
    <org_study_id>16/38</org_study_id>
    <nct_id>NCT02866448</nct_id>
  </id_info>
  <brief_title>Impact of isoQUercetin and Aspirin on Platelet Function</brief_title>
  <acronym>QUAP</acronym>
  <official_title>The Impact of Isoquercetin and Aspirin on Platelet Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Reading</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biotechnology and Biological Sciences Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Quercegen Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Reading</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of acute isoquercetin supplementation,&#xD;
      aspirin, and isoquercetin/aspirin combination on platelet aggregation, blood pressure and&#xD;
      vasculat stiffness (eg digital volume pulse), as well as investigating the plasma&#xD;
      accumulation and urine excretion profiles of quercetin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular disease (CVD) is the leading cause of death worldwide. In 2012, approximately&#xD;
      17.5 million people worldwide died from CVD, representing 31% of global death. Flavonoids are&#xD;
      a class of plant secondary metabolites, functioning in the plant to aid in growth. These&#xD;
      compounds are found in diets worldwide, and many cohort studies have demonstrated the&#xD;
      protective effect of diets high in flavonoids against CVD events, with some studies showing&#xD;
      flavonoid intake inversely associated with CV event risk, CV non-fatal events and all-cause&#xD;
      mortality. One consistent issue with quercetin as a dietary flavonoid is the plasma&#xD;
      concentrations it is able to reach are not always sufficient to provide a protective effect.&#xD;
      Therefore, supplementation or pharmacological intervention with flavonoids may offer a&#xD;
      solution. Supplementation with isoquercetin, the 3-O-glucoside of quercetin, offers the&#xD;
      potential for much higher plasma concentrations of quercetin and its metabolites than dietary&#xD;
      sources can offer, with associated increased inhibitory, anti-platelet effects. It must&#xD;
      therefore be addressed whether isoquercetin supplementation can effectively reduce platelet&#xD;
      function ex vivo, measured by aggregation and closure time, as well as improve vascular&#xD;
      function, measured through blood pressure (BP) and vascular stiffness (eg digital volume&#xD;
      pulse (DVP)).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Funding delayed beyond acceptable start date&#xD;
  </why_stopped>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in platelet aggregation</measure>
    <time_frame>Acute Study: measured at -60 (baseline), 120, 240 and 360min</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Closure Time (CT), measured with a Platelet Function Analyzer (PFA)</measure>
    <time_frame>Acute study: measured at -60 (baseline), 120, 240 and 360min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in blood pressure (systolic pressure, diastolic pressure and pulse pressure)</measure>
    <time_frame>Acute study: measured at -60 (baseline), 0, 30, 60, 90, 120, 180, 240, 300 and 360min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in arterial stiffness measured by digital volume pulse - stiffness index</measure>
    <time_frame>Acute study: measured at -60 (baseline), 0, 30, 60, 90, 120, 180, 240, 300 and 360min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in arterial stiffness measured by digital volume pulse - reflection index</measure>
    <time_frame>Acute study: measured at -60 (baseline), 0, 30, 60, 90, 120, 180, 240, 300 and 360min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total plasma quercetin concentration (micromolar)</measure>
    <time_frame>Acute study: measured at -60 (baseline), 0, 30, 60, 90, 120, 180, 240, 300 and 360min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total urine quercetin concentration (micromolar)</measure>
    <time_frame>Acute study: measured at 0 (baseline),120, 240 and 360min</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Vehicle control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will consume&#xD;
4 x 250mg cellulose capsules containing 250mg cellulose, 62mg Ascorbic acid (Vitamin C), 5mg Nicotinic acid (Vitamin B3) and 0.25mg Folic Acid&#xD;
1 x 75mg cellulose pill</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isoquercetin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will consume&#xD;
4 x 250mg isoquercetin capsules containing 250mg isoquercetin, 62mg Ascorbic acid (Vitamin C), 5mg Nicotinic acid (Vitamin B3) and 0.25mg Folic Acid&#xD;
1 x 75mg cellulose pill</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will consume&#xD;
1 x 75mg dispersible aspirin&#xD;
4 x 250mg cellulose capsules containing 250mg cellulose, 62mg Ascorbic acid (Vitamin C), 5mg Nicotinic acid (Vitamin B3) and 0.25mg Folic Acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isoquercetin plus Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will consume&#xD;
4 x 250mg isoquercetin capsules containing 250mg isoquercetin, 62mg Ascorbic acid (Vitamin C), 5mg Nicotinic acid (Vitamin B3) and 0.25mg folic acid&#xD;
1 x 75mg dispersible aspirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle control</intervention_name>
    <description>Described in arm</description>
    <arm_group_label>Vehicle control</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoquercetin</intervention_name>
    <description>Described in arm</description>
    <arm_group_label>Isoquercetin</arm_group_label>
    <other_name>IsoQ, IsoQblend</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Described in arm</description>
    <arm_group_label>Aspirin</arm_group_label>
    <other_name>ASA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoquercetin plus Aspirin</intervention_name>
    <description>Described in arm</description>
    <arm_group_label>Isoquercetin plus Aspirin</arm_group_label>
    <other_name>IsoQ + ASA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Plasma TAG (triacylglycerol) &lt; 4.0 mmol/l&#xD;
&#xD;
          -  Body mass index (BMI) between 18-35 kg/m2&#xD;
&#xD;
          -  Total cholesterol (TC): &lt;7 mmol/l&#xD;
&#xD;
          -  Systolic blood pressure &lt;160 mmHg and diastolic blood pressure &lt;100 mmHg&#xD;
&#xD;
          -  Consume less than 5 portions of fruit/vegetables per day&#xD;
&#xD;
          -  Male&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Suffered a myocardial infarction/stroke in the past 12 months&#xD;
&#xD;
          -  Diabetic (diagnosed as fasting blood glucose &gt;7 mmol/l) or suffer from other endocrine&#xD;
             disorders&#xD;
&#xD;
          -  Suffering from renal or bowel disease or have a history of cholestatic liver or&#xD;
             pancreatitis&#xD;
&#xD;
          -  On drug treatment for hyperlipidaemia, hypertension, inflammation or hypercoagulation&#xD;
&#xD;
          -  History of alcohol abuse&#xD;
&#xD;
          -  Planning or on a weight reducing regime&#xD;
&#xD;
          -  Undertake vigorous exercise more than 3 times a week&#xD;
&#xD;
          -  Taking nutritional supplements (e.g. fish oil, calcium)&#xD;
&#xD;
          -  Taking flavonoid supplements&#xD;
&#xD;
          -  Suffering from hayfever&#xD;
&#xD;
          -  Taking any, or intolerant to, NSAIDS including aspirin&#xD;
&#xD;
          -  On any medication, prescribed or not prescribed (or willing to abstain from these&#xD;
             during period of study as well as prior 2 week washout period)&#xD;
&#xD;
          -  Using any recreational drugs&#xD;
&#xD;
          -  Vegan&#xD;
&#xD;
          -  Intolerant/allergic to nuts, wheat, dairy&#xD;
&#xD;
          -  Intolerant/allergic to aspirin&#xD;
&#xD;
          -  On, or have taken antibiotics in the last 2 months&#xD;
&#xD;
          -  Had surgery in the last 3 months&#xD;
&#xD;
          -  Smokers, or have smoked in the last month&#xD;
&#xD;
          -  Using e-cigarettes&#xD;
&#xD;
          -  Anaemic: haemoglobin &lt;12.5 g/dl&#xD;
&#xD;
          -  History of gastric ulcers&#xD;
&#xD;
          -  Female&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie A Lovegrove, BSc PhD RNutr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Reading</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Reading</name>
      <address>
        <city>Reading</city>
        <state>Berkshire</state>
        <zip>RG6 6AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>August 2, 2016</study_first_submitted>
  <study_first_submitted_qc>August 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2016</study_first_posted>
  <last_update_submitted>November 28, 2016</last_update_submitted>
  <last_update_submitted_qc>November 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Reading</investigator_affiliation>
    <investigator_full_name>Julie Lovegrove</investigator_full_name>
    <investigator_title>Head of Hugh Sinclair Unit of Human Nutrition</investigator_title>
  </responsible_party>
  <keyword>Cardiovascular disease</keyword>
  <keyword>Flavonoid</keyword>
  <keyword>Isoquercetin</keyword>
  <keyword>Aspirin</keyword>
  <keyword>Platelet function</keyword>
  <keyword>Vascular function</keyword>
  <keyword>Blood pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will be averaged (some will also be normalized) before publishing, IPD (Individual Participant Data) will not be made available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

